chartexchange

Sionna Therapeutics Reports Third Quarter 2026 Financial Results

GlobeNewswire Inc. | Nov 10, 2026 7:00 AM EST

Advancing SION-451 + SION-2222 dual combination to AscenSION CF Phase 2 proof-of-concept trial, expected to initiate in the first quarter of 2027

Read original article